Loading...
Market
What will be the percentage increase in lifespan shown in the first human trial results for the anti-IL-11 therapy by December 31, 2025?
2
Resolution / Starting Odds
0-10% • 25%
11-20% • 25%
21-30% • 25%
More than 30% • 25%
Results published in peer-reviewed medical journals
Story
New Anti-Ageing Therapy Extends Lifespan of Mice by 25%, Reduces Cancer
Jul 18, 2024, 01:06 AM
A new anti-ageing therapy has been shown to extend the lifespan of mice by nearly 25%, according to a study published in Nature. The therapy involves inhibiting interleukin-11 (IL-11), a pro-inflammatory cytokine, which leads to significant health benefits and increased longevity in mice. Both genetic deletion and an anti-IL-11 drug were effective in extending the lifespan of male mice by 22.5% and female mice by 25%. The treated mice, dubbed 'supermodel grannies' due to their youthful appearance, were healthier, stronger, and had fewer age-related health problems. The therapy also reduced the incidence of cancer. This breakthrough has raised hopes for similar anti-ageing treatments in humans, with the anti-IL-11 antibody already in early clinical trials for other conditions such as lung fibrosis.
View original story
Similar markets
0%-10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Lifespan Extension • 25%
Cancer Reduction • 25%
Gray Hair Reduction • 25%
Other • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Increased lifespan • 25%
Improved healthspan • 25%
Reduced inflammation • 25%
Other • 25%